Using single cell RNA sequencing data from a panel of 20 primary AML specimens of various genetic/cytogenetic subgroups, we could further determine that IL1RAP may represent a good therapeutic target in other AML subgroups including t(6;9) AML (only 2 specimens tested) and those with core binding factor translocations. This evidence concerns the gene IL1RAP and acute myeloid leukemia.